Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4500 participants.

Also called NCT04718025

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04718025
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04718025. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-07 (actual); primary completion 2024-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome
Acronym
ELECTRA-SIRIO
Condition
STEMI
Condition
NSTEMI
Condition
Unstable Angina
Intervention (Drug)
Ticagrelor 90mg
Intervention (Drug)
Ticagrelor 60mg
Intervention (Drug)
Aspirin
Lead sponsor
Collegium Medicum w Bydgoszczy (class: other)
Collaborator
Medical Research Agency, Poland (class: other government)

Record details

Record id
cardio:ct-nct04718025
Content hash
15a9c395ae6d9ae11517b0c0d316fa5628ec11412c23d39cb853525232fbfefb